Results: Of 58,498 subjects, 581 (1.0%) had elevated CA 19-9 levels. Multivariate analyses revealed that older age, female sex, lower BMI, and diabetes were independent predisposing factors for elevated CA 19-9 level. A subgroup analysis revealed that the causative conditions were identified in 129 of 351 subjects (36.8%). Among them, the causative conditions in 31 subjects (8.8%, including four cases of cancer and 15 of benign tumors) were not detected at the initial check-up and were found during the follow-up period.
INTRODUCTION
Cancer antigen , an intracellular adhesion molecule, is a tumor marker which is used primarily in the management of biliary tract and pancreatic cancers. [1] [2] [3] [4] [5] Its levels are elevated in most patients with advanced pancreatic cancer and may also be elevated in many kinds of gastrointestinal cancer; e.g., esophageal, stomach, and colorectal cancers as well as hepatocellular carcinoma. [6] [7] [8] [9] [10] Additionally, CA 19-9 levels may be elevated in individuals with liver cirrhosis, chronic hepatitis, pancreatitis, diseases of the bile ducts, ovarian cystic tumors, chronic renal failure, rheumatic diseases, thyroid diseases, and several benign lung diseases. [11] [12] [13] [14] [15] According to guidelines from the American Society of Clinical Oncology, screening for CA 19-9 is not useful as a tool for diagnosing cancer. 16) The test may wrongly indicate normal levels of CA 19-9 in individuals with pancreato-biliary cancer and can also indicate increased levels in individuals without cancer. 17, 18) Nevertheless, as the population of individuals that receive regular health examinations increases, we frequently observe elevated CA 19-9 in healthy individuals. In such cases, additional tests are usually performed to determine the cause of the elevation, including imaging, endoscopy, and/or biopsy. However, the next steps remain uncertain in cases in which the cause remains undetermined after these tests.
Previous studies showed that CA 19-9 levels have no value in screening for asymptomatic individuals because the positive value is extremely low. 7, 8, 19) Furthermore, there has been little long-term followup study on asymptomatic healthy subjects. Only three follow-up studies have been performed, which reported elevated CA 19-9 levels in 0.8%-1.7% of healthy individuals and identified the causative conditions in 25.5%-30.3% of subjects with elevated CA 19-9 levels. 17, 18, 20) However, short follow-up periods and inadequate investigations of the factors related to elevated CA 19-9 levels may have led to inaccurate results.
This study investigated the clinical characteristics of individuals with elevated CA 19-9 levels identified during general health inspections. Additionally, we tried to determine the need for medical followup in individuals with elevated CA 19-9 levels based on the results of their follow-ups. 
METHODS

Patients
Elevated Cancer Antigen 19-9 and Control Groups
Subjects with elevated CA 19-9 levels were placed into the elevated CA 19-9 group and all others into the control group. The serum level of CA 19-9 was measured using a CA 19-9 kit (Riakey CA 19-9 IRMA tube; Shinjin Medics Inc., Goyang, Korea) in which a value of >37 U/mL indicated a significant elevation of CA 19-9. We compared the two in women. Levels of AFP >10 ng/mL, CEA >5 ng/mL in non-smokers (>7.5 in smokers), and CA 125 >35 U/mL indicated significant elevations.
Statistical Analysis
The categorical variables were summarized as numbers (%) and ana- 
RESULTS
Comparisons between the Elevated Cancer Antigen 19-9 and Control Groups
Among the 58,676 subjects visiting our health care center, 178 were excluded from the study for inappropriate or poor answers on the questionnaires or for young age ( Figure 1 ). Overall, 581 subjects (1.0%)
were assigned to the elevated CA 19-9 group and 57,917 to the control group. Four hundred and thirty subjects (74.0%) in the elevated CA 19-9 group and 26,847 subjects (46.4%) in the control group were female ( Table 1 
Predisposing Factors for Elevated Cancer Antigen 19-9 Levels
Subjects with elevated CA 19-9 levels were generally older (P<0.001);
predominantly female (P<0.001); had a lower BMI (P<0.001); were non-smokers (P<0.001) and non-drinkers (P<0.001); showed a higher incidence of diabetes (P<0.001), hypertension (P=0.019), and congestive heart disease (P=0.012); and were more likely to be on antiplatelet agents (P<0.001) and nonsteroidal anti-inflammatory drugs medication (P=0.034) than the control group ( P<0.001) were independent predisposing factors for elevated CA 19-9 levels ( Table 2) .
Causative Conditions in the Elevated Cancer Antigen 19-9 Group
Among the subjects in the elevated CA 19-9 group, causative condi- 
Subgroup Analyses
Of the 581 subjects with elevated CA 19-9 levels, 230 were excluded from subgroup analysis for the reasons described in the methods section. Of 351 subjects analyzed, the mean number of CA 19-9 tests was 3.99±2.29 and the total follow-up period of hospital visits was 42±23.9
months. The causative condition(s) were detected in 129 subjects (36.8%, group A) during the entire follow-up period, while no caus- 
Causative Conditions Found during Follow-up in Group A
The causative conditions of 31 subjects (8.8% of the subgroup, 32 cases) with elevated CA 19-9 levels were not detected on initial check-up and were identified during the follow-up period ( 
DISCUSSION
Our results showed that serum CA 19-9 levels are elevated in about 1%
of health examinees and that elevated levels are more common in elderly individuals, women, diabetics, and individuals with low BMI.
The causative conditions were confirmed as benign tumors and cancer in 67 and 25 cases, respectively. In other words, cancers related to increased CA 19-9 level were found in only 0.04% of all cases. Additionally, in many cases, CA 19-9 findings did not play a major role in detecting cancer. Therefore, if the objective of the CA 19-9 test is to detect early cancer, the test is costly and inefficient, as previous studies showed. 1, 9, 16) Thus, CA 19-9 is not suitable as a diagnostic marker for cancer in healthy individuals.
In previous studies, the percentages of subjects with elevated CA 19-9 levels ranged from 0.8% to 1.7%. 17, 18, 20) The reason for the relatively low prevalence rate in our study was that the proportions of women and elderly people in the population were lower than those in other studies. In addition, our study identified diabetes mellitus as an independent predisposing factor for elevated CA 19-9 level. This result indirectly supports previous findings that diabetes might be increasingly associated with pancreatic mass such as pancreatic cancer and pan- Chronic viral hepatitis included 22 subjects with hepatitis B and four with hepatitis C. Biliary stone included 35 cases of gall bladder stone and one each with common bile duct stone and intrahepatic duct stone, respectively. Thyroid disease included two cases with hyperthyroidism, 13 with hypothyroidism, and four with thyroiditis. Inflammatory bowel disease included one case of ulcerative colitis and one with Crohn's disease. Active tuberculosis included three cases of pulmonary tuberculosis and one case of tuberculosis colitis. Histological classifications of benign ovarian tumors confirmed by operation were as follows: endometriosis of ovary, 10; mature cystic teratoma, 4; follicular cyst, 1; cystic mesothelioma, 1; seromucinous borderline tumor, 1; and dermoid cyst, 1. CA 199, cancer antigen 199.
creatic neuroendocrine tumors. 5, [21] [22] [23] In subgroup analysis, the causative conditions were detected in 129 subjects (36.8%) and the causative conditions of 31 subjects were not detected on initial check-up but were identified during the follow-up period. Cancer and benign tumors were found during follow-up in four and 14 subjects, respectively. Therefore, a large number of tumors may be found during follow-up study. Additionally, eight patients (6.2%) from group A died during the follow-up period due to the causative cancers in all cases.
Therefore, follow-up testing for individuals with elevated CA 19-9 levels may be helpful.
Our review of the cases of causative tumors detected during the follow-up period highlights the need for follow-up tests. In the case of the subject with cholangiocarcinoma (Supplementary Table 1 , case 1), the initial CT scan result was normal. However, 14 months later, cholangiocarcinoma with liver metastasis was found in the follow-up CT scan. In the case of other cancers (cases 2, 3, and 4), the cancers were detected in their early stages by continuous monitoring and were completely cured after surgery. Additionally, in many benign tumor cases (cases 8, 9, 11, 13, and 14), CA 19-9 levels were normalized after surgical resection of the tumors.
Elevated CEA and CA 125 levels were more common in group A than in group B because there were many gastrointestinal cancer and ovarian tumor cases in group A. However, in 28 cases of benign ovarian tumor (65.1%) and one case of ovarian cancer (50%), CA 19-9 levels increased without elevation of CA 125 levels. Therefore, evaluation of gynecologic disorders may be needed for women with elevated CA 19-9 and normal CA 125 levels.
Our study has some limitations. Firstly, the sample size was not large enough for conclusions regarding the optimal screening interval and indispensable inspection items based on our results. In our study, the In conclusion, serum CA 19-9 levels were elevated in about 1% of health examinees, more commonly in elderly individuals, women, diabetics, and individuals with low BMI. The causative conditions were detected in 36.8% of subjects with elevated CA 19-9 levels; in 8.8% of the subjects, the causative conditions were not detected on initial check-up but were found during the follow-up period. Therefore, the use of CA 19-9 as a screening test for cancer in healthy individuals is inappropriate. However, follow-up tests for individuals with elevated CA 19-9 levels may be needed because some clinically significant causative diseases may be found during follow-up.
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was reported. 
SUPPLEMENTARY MATERIALS
